Literature DB >> 8613739

Facilitation of olfactory learning by a modulator of AMPA receptors.

J Larson1, T Lieu, V Petchpradub, B LeDuc, H Ngo, G A Rogers, G Lynch.   

Abstract

The effects of a benzoyl-piperidine drug (BDP) that facilitates AMPA receptor-mediated synaptic responses were tested on the acquisition and retention of long-term memory at dosages that had no detectable effects on a variety of performance measures. BDP-12 produced a dose-dependent suppression of exploratory activity in rats with statistically reliable effects occurring at 50 mg/kg (i.p.). The drug had no effects on balance beam performance at 30 mg/kg but at 45 mg/kg reduced the number of crossings made within a session; it did not, however, affect the time required to perform a traversal. The performance of well-trained rats presented with a familiar pair of odors (correct and incorrect) was not not detectably altered by BDP-12 at 30 mg/kg; however, the number of correct responses made in a five-trial test was reduced at 45 mg/kg. These results indicate that the AMPA receptor modulator at 30 mg/kg has little influence on arousal, motivation, sensori-motor processing, and attention; higher dosages cause a depression of learned and unlearned prepotent responses. The effects of the lower concentration were tested on two-odor discrimination learning in rats that had extensive training on the task. The animals (n = 20) were given three or five acquisition trials with novel odor pairs immediately after an injection of drug or vehicle and then tested 1-3 d later for retention in five unrewarded probe trials. Retention performance was not significantly better than chance 52.6 +/- 4.5% correct) for odors learned on vehicle injection days but was well above chance for odors learned on drug injection days (70.6 +/- 4.2% correct). Within-subject comparisons confirmed the memory enhancing effect of BDP-12 (p < 0.01). Analyses of performance during five training trials indicated that the rats made more correct responses on days on which they were given the drug than on days on which they were injected with vehicle (p < 0.02). Within-subject differences in acquisition were correlated with differences in retention (r = 0.70). There were no evident effects of the drug on response latencies during acquisition. These results suggest that AMPA receptor modulators reduce the amount of training needed for the formation of long-term memory and do so at dosages which have little effect on variables that secondarily influence acquisition. Possible reasons for this selectivity are discussed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8613739      PMCID: PMC6577953     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  19 in total

1.  AMPA receptor facilitation accelerates fear learning without altering the level of conditioned fear acquired.

Authors:  M T Rogan; U V Stäubli; J E LeDoux
Journal:  J Neurosci       Date:  1997-08-01       Impact factor: 6.167

2.  Mutations in ionotropic AMPA receptor 3 alter channel properties and are associated with moderate cognitive impairment in humans.

Authors:  Ye Wu; Amy C Arai; Gavin Rumbaugh; Anand K Srivastava; Gillian Turner; Takashi Hayashi; Erika Suzuki; Yuwu Jiang; Lilei Zhang; Jayson Rodriguez; Jackie Boyle; Patrick Tarpey; F Lucy Raymond; Joke Nevelsteen; Guy Froyen; Mike Stratton; Andy Futreal; Jozef Gecz; Roger Stevenson; Charles E Schwartz; David Valle; Richard L Huganir; Tao Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-07       Impact factor: 11.205

Review 3.  Therapeutic potential of positive AMPA receptor modulators in the treatment of neuropsychiatric disorders.

Authors:  Stefano Marenco; Daniel R Weinberger
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

4.  Glutamate receptor-mediated restoration of experience-dependent place field expansion plasticity in aged rats.

Authors:  Sara N Burke; Andrew P Maurer; Zhiyong Yang; Zaneta Navratilova; Carol A Barnes
Journal:  Behav Neurosci       Date:  2008-06       Impact factor: 1.912

5.  Allosteric modulation of AMPA-type glutamate receptors increases activity of the promoter for the neural cell adhesion molecule, N-CAM.

Authors:  B D Holst; P W Vanderklish; L A Krushel; W Zhou; R B Langdon; J R McWhirter; G M Edelman; K L Crossin
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

6.  Atypical Endocannabinoid Signaling Initiates a New Form of Memory-Related Plasticity at a Cortical Input to Hippocampus.

Authors:  Weisheng Wang; Yousheng Jia; Danielle T Pham; Linda C Palmer; Kwang-Mook Jung; Conor D Cox; Gavin Rumbaugh; Daniele Piomelli; Christine M Gall; Gary Lynch
Journal:  Cereb Cortex       Date:  2018-07-01       Impact factor: 5.357

Review 7.  Pharmacology of AMPA/kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders.

Authors:  G J Lees
Journal:  Drugs       Date:  2000-01       Impact factor: 9.546

8.  Mechanisms underlying cognitive enhancement and reversal of cognitive deficits in nonhuman primates by the ampakine CX717.

Authors:  R E Hampson; R A España; G A Rogers; L J Porrino; S A Deadwyler
Journal:  Psychopharmacology (Berl)       Date:  2008-11-05       Impact factor: 4.530

9.  A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.

Authors:  Donald C Goff; J Steven Lamberti; Andrew C Leon; Michael F Green; Alexander L Miller; Jayendra Patel; Theo Manschreck; Oliver Freudenreich; Steven A Johnson
Journal:  Neuropsychopharmacology       Date:  2007-05-09       Impact factor: 7.853

10.  Reversal of cognitive deficits by an ampakine (CX516) and sertindole in two animal models of schizophrenia--sub-chronic and early postnatal PCP treatment in attentional set-shifting.

Authors:  Brian Villumsen Broberg; Birte Yding Glenthøj; Rebecca Dias; Dorrit Bjerg Larsen; Christina Kurre Olsen
Journal:  Psychopharmacology (Berl)       Date:  2009-04-24       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.